Entera Bio Ltd.
NASDAQ:ENTXBiotechnology
+$0.00 today
- Market cap
- $567.69M
- Beta
- 1.49
- P/E (TTM)
- -4.6
- EPS (TTM)
- -$0.26
Volume 0.49M
Average 0.16M
ENTX Net Receivables
Amounts owed to the company by customers and others, net of allowances for uncollectible accounts.
Entera Bio Ltd.NASDAQ: ENTX
Net Receivables · Q1 FY2026 · quarter ended Mar 2026
Net receivables remains negative
Q1 FY2026 net receivables was $0, compared with $126K a year earlier. Over 3 fiscal years it compounded at -3.8% a year.
Context
- Net receivables amounted to 0.0% of total assets at the end of Q1 FY2026, down 0.6 pp from a year earlier.
- Net receivables increased in 2 of the last 3 fiscal years.
What to watch
Whether net receivables keeps falling in the next quarterly balance sheet after a -100.0% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Net Receivables history
USD · from the balance sheet
- Latest · FY2025
- 219K USD
- Year-over-year change
- +73.8%
- 4-year CAGR
- +4.6%
| Period | Period end | Net Receivables | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 219K | +73.8% |
| FY2024 | 2024-12-31 | 126K | — |
| FY2023 | 2023-12-31 | 0 | -100.0% |
| FY2022 | 2022-12-31 | 246K | +34.4% |
| FY2021 | 2021-12-31 | 183K | — |
Net Receivables vs competitors
How ENTX compares with its peers on the latest reported figures
- ENTX's Mar 2026 net receivables of $0 is the 8th highest of the 10 companies compared; the peer median is $233K.
- Its year-over-year change of -100.0% is the 7th highest of 9, against a peer median of -68.8%.
- Net receivables amounts to 0.0% of total assets for ENTX, versus a peer median of 0.4%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Mar 2026 | $54.06M | +15171.8% | -12.6% | 29.0% | |
| Mar 2026 | $4.26M | -20.5% | -5.3% | 1.6% | |
IRDOpus Genetics, Inc. | Mar 2026 | $2.72M | -42.9% | -13.3% | 4.1% |
| Mar 2026 | $772K | +105.3% | — | 0.6% | |
| Mar 2026 | $233K | -94.7% | — | 0.2% | |
| Apr 2026 | $56K | — | — | 0.4% | |
| Mar 2026 | $44K | -99.8% | +186.1% | 0.1% | |
| Mar 2026 | $0 | -100.0% | -3.8% | 0.0% | |
| Mar 2026 | $0 | -100.0% | -96.6% | 0.0% | |
| Mar 2026 | $0 | -100.0% | — | 0.0% | |
| Peer median (excluding ENTX) | $233K | -68.8% | -12.6% | 0.4% | |
Competitors are the stored peer set for ENTX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Entera Bio Ltd.
NASDAQ:ENTX
Intrinsic Alpha fair value
Locked
Current Price
$3.26
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.